Descrizione del progetto
Una diagnosi semplice dell’endometriosi
L’endometriosi è una malattia caratterizzata dalla crescita di un tessuto analogo a quello del rivestimento uterino al di fuori di tale organo, che colpisce in tutto il mondo milioni di donne in età riproduttiva. La diagnosi solitamente prevede un esame pelvico, gli ultrasuoni o la RMI e, in alcuni casi, l’esame laparoscopico dell’addome. Finanziato dal Consiglio europeo per l’innovazione, il progetto Endosolve propone di semplificare e migliorare la diagnosi dell’endometriosi introducendo un biomarcatore digitale di nuova concezione. Il test ha già dimostrato risultati promettenti nell’ambito di studi preclinici ed esplorativi su volontari umani, e ora sono necessarie ulteriori fasi di perfezionamento e convalida in un ambiente clinico, nonché lo sviluppo di un modello commerciale.
Obiettivo
Endometriosis is a chronic inflammatory disease defined as the presence of endometrium-like tissue outside the uterus. Establishment and growth of such endometriotic tissue is estrogen-dependent, thus it is mostly found in women of reproductive age. It is estimated that currently at least 190 million women and adolescent girls worldwide are affected by the disease during reproductive age although some women may suffer beyond menopause
She Sense is an accurate and non-invasive test that enables simpler, earlier and more cost-effective diagnosis of patients with endometriosis
Project scope: Experimental proof of principle for the novel digital biomarker has been demonstrated using early generation prototypes for research purposes in a pre-clinical model and exploratory human volunteer study. Sision Medical seeks to mature this technology and validate its use as a clinically acceptable diagnostic test.
Therefore, the scope of this project will focus on the advancement of the She Sense test to investor readiness by;
Further refinement of the signal processing to optimise the digital biomarker performance
Validation of the biomarker in a clinical setting
Development of a sustainable business case and business model towards commercialisation
The end point of the project is the compilation and evaluation of data obtained in a prospective clinical study. EIC funding will enable Sision Medical to enhance the technology efficacy and validation in a clinical setting. This will pave the path for larger studies which will demonstrate clinically acceptable sensitivity and specificity of the She Sense diagnostic test.
Parole chiave
Programma(i)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Invito a presentare proposte
(si apre in una nuova finestra) HORIZON-EIC-2022-TRANSITION-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-EIC -Coordinatore
H91CV96 Galway
Irlanda
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.